EuroBiotech: More Articles of Note

> AstraZeneca ($AZN) became the latest European biopharma to have its tax model scrutinized. The Guardian, which ran the investigation into the company, claimed AstraZeneca made loans worth $2.7 billion (€2.4 billion) through a Dutch subsidiary. Richard Murphy, an accountant and the author of The Joy of Tax, thinks the purpose of the model is clear. "The structure only appears to exist for tax purposes, to try to secure a tax advantage," he said. The Guardian

> Servier offloaded novel kinase inhibitors to Horizon Discovery (AIM:HZD), which plans to apply its CRISPR-Cas9 gene editing and combination screening technology to the programs. The deal gives Servier the option to take back the assets in return for a commitment to pay milestones that could total more than £50 million ($77 million). If Servier opts against reclaiming the assets, Horizon will be free to shop the programs to other potential buyers. Release

> Cancer Research UK committed £15 million ($23 million) to research initiatives at academic centers in Britain. University College London took home the biggest slice of the cash, pocketing £5 million to research how immune responses develop and why they stop. The soon-to-open Francis Crick Institute picked up £4.2 million to finance experimental cancer research. Statement

> Genmab (CPH:GEN) received a $3 million (€2.7 million) milestone payment from Johnson & Johnson ($JNJ). The payout relates to the advance of a preclinical program at J&J subsidiary Janssen Biotech that is making use of Genmab's DuoBody technology platform. The bispecific antibody platform is the centerpiece of the heavily backloaded deal Janssen entered into with Genmab in 2012, the scope of which was expanded the following year. Release

> Adaptimmune Therapeutics ($ADAP) detailed plans to move into a 67,000-square-foot facility near to its home city of Oxford. The new site can house 200 researchers, giving Adaptimmune the space to broaden its immuno-oncology R&D operations. Adaptimmune expects the new building to be ready late next year, around 8 years after it started research operations nearby with a staff of three. FierceBiotech

> Innate Pharma (EPA:IPH) opened another trial of its NKG2A checkpoint inhibitor, IPH2201. The Phase I/II study will administer IPH2201 in combination with Imbruvica to 45 people with relapsed or refractory chronic lymphocytic leukemia. Innate is already trialling IPH2201 as a single-agent treatment for squamous cell carcinoma and ovarian cancer. A fourth study, combining IPH2201 with Erbitux, is due to start in the coming months. Release